Diamyd expects to begin reporting Phase III results in late spring 2011
Diamyd Medical's President and CEO Elisabeth Lindner states in the CEO
comments in today's quarterly report that the Company expects to begin
reporting the results from the European Phase III trial in type 1
diabetes as planned in late spring 2011.
"When all patients have completed their 15-month visit in the European
study, much work will lie ahead in the form of collecting the remaining
documentation from the more than 60 participating clinics throughout
Europe and from our central laboratory, which carry out all the
analysis", says Elisabeth Lindner, CEO and President of Diamyd Medical.
"Furthermore, all data will be compiled and, according to our plan, the
trial will eventually be unblinded and we expect to begin reporting the
results in late spring 2011.”
During the report period Diamyd Medical announced that the screening of
patients for the US Phase III study DiaPrevent was completed. All
patients are enrolled in the study and the Company expects to be able to
present the 15-month results during the summer 2012.
During the period the Company further reported promising data in a
clinical Phase I trial investigating the drug candidate NP2 Enkephalin
as a potential therapy for severe cancer pain. Substantial and sustained
reduction in experienced pain was reported in the two highest dose
cohorts and no drug related Serious Adverse Events have been reported by
any patient included in the trial. After the end of the period, the
first patient has been included in a placebo-controlled Phase II study
with NP2 Enkephalin that will encompass approximately 32 patients with
severe cancer pain. Screening of patients for the study is proceeding at
a brisk pace and nine clinics are now operational.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Phone: +46 8 661 0026
